Correction to IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

Carlo Palmieri; Rob C. Stein; Xinxue Liu; Emma Hudson; Hanna Nicholas; Hironobu Sasano; Fouzia Guestini; Chris Holcombe; Sophie Barrett; Laura Kenny; Sadie Reed; Adrian Lim; Larry Hayward; Sacha Howell; R. Charles Coombes; IRIS trial participants

doi:10.1007/s10549-017-4539-3

Correction to IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

Carlo Palmieri^*, Rob C. Stein, Xinxue Liu, Emma Hudson, Hanna Nicholas, Hironobu Sasano, Fouzia Guestini, Chris Holcombe, Sophie Barrett, Laura Kenny, Sadie Reed, Adrian Lim, Larry Hayward, Sacha Howell, R. Charles Coombes, IRIS trial participants

^*Corresponding author for this work

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: ‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.

Original language	English
Pages (from-to)	1
Number of pages	1
Journal	Breast Cancer Research and Treatment
Early online date	25 Oct 2017
DOIs	https://doi.org/10.1007/s10549-017-4539-3
Publication status	Published - 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-017-4539-3

Cite this

Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Nicholas, H., Sasano, H., Guestini, F., Holcombe, C., Barrett, S., Kenny, L., Reed, S., Lim, A., Hayward, L., Howell, S., Charles Coombes, R., & IRIS trial participants (2017). Correction to IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Research and Treatment, 1. https://doi.org/10.1007/s10549-017-4539-3

@article{e62db747de8e41eca3cbde5c82f2e91f,

title = "Correction to IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients",

abstract = "In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: {\textquoteleft}The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre{\textquoteright}.",

author = "Carlo Palmieri and Stein, {Rob C.} and Xinxue Liu and Emma Hudson and Hanna Nicholas and Hironobu Sasano and Fouzia Guestini and Chris Holcombe and Sophie Barrett and Laura Kenny and Sadie Reed and Adrian Lim and Larry Hayward and Sacha Howell and {Charles Coombes}, R. and {IRIS trial participants}",

year = "2017",

doi = "10.1007/s10549-017-4539-3",

language = "English",

pages = "1",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer Nature",

}

Palmieri, C, Stein, RC, Liu, X, Hudson, E, Nicholas, H, Sasano, H, Guestini, F, Holcombe, C, Barrett, S, Kenny, L, Reed, S, Lim, A, Hayward, L, Howell, S, Charles Coombes, R & IRIS trial participants 2017, 'Correction to IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients', Breast Cancer Research and Treatment, pp. 1. https://doi.org/10.1007/s10549-017-4539-3

TY - JOUR

T1 - Correction to IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

AU - Palmieri, Carlo

AU - Stein, Rob C.

AU - Liu, Xinxue

AU - Hudson, Emma

AU - Nicholas, Hanna

AU - Sasano, Hironobu

AU - Guestini, Fouzia

AU - Holcombe, Chris

AU - Barrett, Sophie

AU - Kenny, Laura

AU - Reed, Sadie

AU - Lim, Adrian

AU - Hayward, Larry

AU - Howell, Sacha

AU - Charles Coombes, R.

AU - IRIS trial participants

PY - 2017

Y1 - 2017

N2 - In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: ‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.

AB - In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: ‘The study was coordinated by the Imperial Clinical Trials Unit—Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre’.

UR - http://www.scopus.com/inward/record.url?scp=85032226093&partnerID=8YFLogxK

U2 - 10.1007/s10549-017-4539-3

DO - 10.1007/s10549-017-4539-3

M3 - Article

AN - SCOPUS:85032226093

SN - 0167-6806

SP - 1

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

ER -

Correction to IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this